Compare · ABT vs SIGA
ABT vs SIGA
Side-by-side comparison of Abbott Laboratories (ABT) and SIGA Technologies Inc. (SIGA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SIGA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $153.59B, about 495.7x SIGA ($309.8M).
- Over the past year, ABT is down 34.3% and SIGA is down 33.6% - SIGA leads by 0.7 points.
- SIGA has been more active in the news (8 items in the past 4 weeks vs 7 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 0 for SIGA).
- Company
- Abbott Laboratories
- SIGA Technologies Inc.
- Price
- $88.09-1.73%
- $4.32+0.35%
- Market cap
- $153.59B
- $309.8M
- 1M return
- +5.08%
- +0.23%
- 1Y return
- -34.26%
- -33.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
SIGA Technologies Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was founded in 1995 and is headquartered in New York, New York.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest SIGA
- Director Marshall Joseph W Iii converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 7% to 246,523 units (SEC Form 4) (withholding tax)
- Director Keane John M converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39) (SEC Form 4) to satisfy withholding obligation
- Director Ford Harold Eugene Jr. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 55% to 47,538 units (SEC Form 4) (withholding obligation)
- Director Phillips Holly L. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to cover withholding tax
- Director Nemirovsky Julian converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to satisfy withholding obligation
- Director Durnan Jaymie A converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 23% to 88,754 units (SEC Form 4) (tax liability)
- Director Nabel Gary J. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) (for tax liability)
- SIGA Technologies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by SIGA Technologies Inc.
- SEC Form 10-Q filed by SIGA Technologies Inc.